WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004093905) HUMAN CYTOMEGALOVIRUS ANTIGENS EXPRESSED IN MVA AND METHODS OF USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/093905    International Application No.:    PCT/US2004/011891
Publication Date: 04.11.2004 International Filing Date: 16.04.2004
IPC:
A61K 39/245 (2006.01), A61K 39/275 (2006.01), C12N 15/863 (2006.01)
Applicants: CITY OF HOPE [US/US]; 1500 East Duarte Road, Duarte, California 91010 (US) (For All Designated States Except US).
DIAMOND, Don, J. [US/US]; (US) (For US Only)
Inventors: DIAMOND, Don, J.; (US)
Agent: FIGG, E., Anthony; 1425 K Street, N.W., Suite 800, Washington, District of Columbia 20005 (US)
Priority Data:
60/463,026 16.04.2003 US
Title (EN) HUMAN CYTOMEGALOVIRUS ANTIGENS EXPRESSED IN MVA AND METHODS OF USE
(FR) ANTIGENES DU CYTOMEGALOVIRUS HUMAIN EXPRIMES DANS VACCINIA ANKARA MODIFIE (MVA), ET METHODES D'UTILISATION
Abstract: front page image
(EN)DNA and protein constructs useful in producing vaccines against human cytomegalovirus contain optionally N-end modified and N-terminal ubiquitinated human cytomegalovirus antigenic proteins, including pp65, pp150, IE1, gB and antigenic fragments thereof. Vaccine viruses, in particular poxviruses such as vaccinia and Modified Vaccinia Ankara, that express the constructs may be used as vaccines to augment the immune response to human cytomegalovirus, both prophylatically and in patients already carrying human cytomegalovirus, as well as to create and expand cytomegalovirus-reactive T cells for transfer of adoptive immunity.
(FR)L'invention concerne des constructions d'ADN et de protéines utiles pour la production de vaccins contre le cytomégalovirus humain. Ces constructions contiennent facultativement des protéines antigéniques du cytomégalovirus humain modifiées par l'extrémité N et transformées en ubiquitine par le N-terminal, dont pp65, pp150, IE1, gB et leurs fragments antigéniques. Des virus de la vaccine, en particulier des poxvirus tels que la vaccine et Vaccinia Ankara modifié, qui expriment ces constructions, peuvent être utilisés comme vaccins pour renforcer la réponse immunitaire au cytomégalovirus humain, tant à des fins prophylactiques chez des patients déjà porteurs du cytomégalovirus humain, que pour créer et diffuser des lymphocytes T réactifs au cytomégalovirus, destinés au transfert de l'immunité adoptive.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)